SURVYR

CTY New listing

City Therapeutics, Inc.
IPO · listed Oct 16, 2026
$20.47
−$0.31 (1.47%)Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-9%-6%-4%-1%+1%Oct 16Oct 23Oct 19
CTYSPY
Wall St. Highest PT $28.43 (+38.9%) Wall St. Avg PT $23.30 (+13.9%)
$20$23$26$28$31POC $21Hi $28Avg $23
Underwater Drawdown %Max DD -8.8%Current -8.6%
0.0%-8.8%
Relative Strength vs SPY-8.2% vs SPYUnderperforming
+12%0%-12%
1W
−$1.93 (8.64%)
1M
–
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for CTY
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.0B
52-week range$19.75 – $23.88
Revenue growth (latest quarter vs a year ago)+14.0%
Dividend yieldNo dividend

What they do

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CTY yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CTY earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 02:54:16 ET
No EPS history available.

News & catalysts

More news
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire · Oct 19
City Therapeutics (CTY) Debuts Strongly But Fair Value Remains Hard To Pin Down
Simply Wall St. · Oct 18
City Therapeutics (CTY) Filed A $239.1 Million Shelf Registration After Its IPO
Simply Wall St. · Oct 18
Another Biotech IPO Pops on Rough Day for Broader Market
Barrons.com · Oct 16
City Therapeutics surges in market debut after upsizing $200M IPO
Investing.com · Oct 16

Stats refreshed 2026-10-24 02:54:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026